Michael Stansky Purchases 410,000 Shares of TriSalus Life Sciences (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Michael Stansky acquired 410,000 shares of TriSalus Life Sciences stock in a transaction that occurred on Friday, May 15th. The stock was acquired at an average cost of $2.50 per share, with a total value of $1,025,000.00. Following the purchase, the director owned 1,240,722 shares in the company, valued at $3,101,805. The trade was a 49.35% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

TriSalus Life Sciences Stock Up 13.1%

Shares of TLSI stock traded up $0.35 on Monday, hitting $3.03. The company’s stock had a trading volume of 773,435 shares, compared to its average volume of 276,402. The company has a debt-to-equity ratio of 2.58, a current ratio of 5.78 and a quick ratio of 5.46. TriSalus Life Sciences, Inc. has a fifty-two week low of $2.20 and a fifty-two week high of $7.95. The firm’s fifty day moving average price is $4.18 and its 200-day moving average price is $5.13. The stock has a market capitalization of $185.77 million, a price-to-earnings ratio of -2.15 and a beta of 0.56.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01. The business had revenue of $13.21 million during the quarter, compared to analyst estimates of $13.20 million. Research analysts anticipate that TriSalus Life Sciences, Inc. will post -0.45 EPS for the current year.

Analyst Upgrades and Downgrades

TLSI has been the subject of several analyst reports. Lake Street Capital reduced their price objective on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Canaccord Genuity Group reduced their price objective on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, March 6th. Finally, Weiss Ratings lowered shares of TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, TriSalus Life Sciences presently has an average rating of “Hold” and a consensus target price of $7.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its position in shares of TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after buying an additional 7,519 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of TriSalus Life Sciences during the second quarter valued at about $47,000. Invesco Ltd. acquired a new position in shares of TriSalus Life Sciences during the fourth quarter valued at about $72,000. Abel Hall LLC acquired a new position in shares of TriSalus Life Sciences during the fourth quarter valued at about $73,000. Finally, HighMark Wealth Management LLC acquired a new position in shares of TriSalus Life Sciences during the fourth quarter valued at about $75,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.